Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hailong Hu

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Cell Metabolism|November 19, 2024
Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndromeShen Li, Hongbo Liu, Hailong Hu, et al.
Molecular Cancer|February 4, 2023
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinomaKaiwei Yang, Hailong Hu, Junlong Wu, et al.
Cancer Science|October 13, 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinomaDingwei Ye, Jiyan Liu, Aiping Zhou, et al.
Cancer Medicine|March 23, 2023
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world studyRuopeng Su, Zeyu Chen, Daoping Hong, et al.
Future Oncology (London, England)|January 8, 2024
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancerGary D Steinberg, Neal D Shore, Joan Palou Redorta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaWang Qu, Cheng Fu, Weiqing Han, et al.
Cancer Medicine|April 6, 2023
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 studySujun Han, Zhigang Ji, Junhui Jiang, et al.
The Journal of Clinical Investigation|December 5, 2023
ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubulesDhanunjay Mukhi, Lingzhi Li, Hongbo Liu, et al.
Cancer|June 24, 2026
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxelShiwang Huang, Kaipeng Jia, Shan Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2025
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder CancerYunkai Qie, Shiwang Huang, Chong Shen, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Cell Metabolism|November 19, 2024
Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndromeShen Li, Hongbo Liu, Hailong Hu, et al.
Molecular Cancer|February 4, 2023
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinomaKaiwei Yang, Hailong Hu, Junlong Wu, et al.
Cancer Science|October 13, 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinomaDingwei Ye, Jiyan Liu, Aiping Zhou, et al.
Cancer Medicine|March 23, 2023
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world studyRuopeng Su, Zeyu Chen, Daoping Hong, et al.
Future Oncology (London, England)|January 8, 2024
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancerGary D Steinberg, Neal D Shore, Joan Palou Redorta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2024
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinomaWang Qu, Cheng Fu, Weiqing Han, et al.
Cancer Medicine|April 6, 2023
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 studySujun Han, Zhigang Ji, Junhui Jiang, et al.
The Journal of Clinical Investigation|December 5, 2023
ACSS2 gene variants determine kidney disease risk by controlling de novo lipogenesis in kidney tubulesDhanunjay Mukhi, Lingzhi Li, Hongbo Liu, et al.
Cancer|June 24, 2026
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxelShiwang Huang, Kaipeng Jia, Shan Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2025
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High-Risk Non-Muscle-Invasive Bladder CancerYunkai Qie, Shiwang Huang, Chong Shen, et al.
Pageof 21